JP2010512414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010512414A5 JP2010512414A5 JP2009541511A JP2009541511A JP2010512414A5 JP 2010512414 A5 JP2010512414 A5 JP 2010512414A5 JP 2009541511 A JP2009541511 A JP 2009541511A JP 2009541511 A JP2009541511 A JP 2009541511A JP 2010512414 A5 JP2010512414 A5 JP 2010512414A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administered
- subject
- baseline
- ambrisentan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 claims 8
- 229960002414 ambrisentan Drugs 0.000 claims 8
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 6
- 230000007423 decrease Effects 0.000 claims 5
- 208000002815 pulmonary hypertension Diseases 0.000 claims 4
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 230000004872 arterial blood pressure Effects 0.000 claims 1
- 230000000386 athletic effect Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000000701 coagulant Substances 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002250 eicosanoid group Chemical group 0.000 claims 1
- 230000000004 hemodynamic effect Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229940127293 prostanoid Drugs 0.000 claims 1
- 210000001147 pulmonary artery Anatomy 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86966706P | 2006-12-12 | 2006-12-12 | |
| PCT/US2007/087058 WO2008073928A1 (en) | 2006-12-12 | 2007-12-11 | Composition for treating a pulmonary hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010512414A JP2010512414A (ja) | 2010-04-22 |
| JP2010512414A5 true JP2010512414A5 (enExample) | 2011-02-03 |
Family
ID=39092031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009541511A Withdrawn JP2010512414A (ja) | 2006-12-12 | 2007-12-11 | 肺高血圧を処置するための組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US20080139593A1 (enExample) |
| EP (2) | EP2952193A1 (enExample) |
| JP (1) | JP2010512414A (enExample) |
| AU (1) | AU2007333115B2 (enExample) |
| CA (1) | CA2669536C (enExample) |
| CY (1) | CY2016017I2 (enExample) |
| DK (1) | DK2101777T3 (enExample) |
| ES (1) | ES2544724T3 (enExample) |
| HK (1) | HK1218393A1 (enExample) |
| HU (2) | HUE025355T2 (enExample) |
| LU (1) | LU93081I2 (enExample) |
| PL (1) | PL2101777T3 (enExample) |
| PT (1) | PT2101777E (enExample) |
| SI (1) | SI2101777T1 (enExample) |
| WO (1) | WO2008073928A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2101777T3 (pl) | 2006-12-12 | 2015-10-30 | Gilead Sciences Inc | Kompozycja do leczenia nadciśnienia płucnego |
| EP2170397A1 (en) | 2007-07-11 | 2010-04-07 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
| JP2010535210A (ja) | 2007-07-31 | 2010-11-18 | ギリード・コロラド・インコーポレーテッド | アンブリセンタンの代謝産物および誘導体 |
| WO2010062640A1 (en) * | 2008-10-28 | 2010-06-03 | Gilead Colorado, Inc. | Methods for treating idiopathic pulmonary fibrosis and associated complications |
| JP2013533882A (ja) * | 2010-06-30 | 2013-08-29 | ギリアード サイエンシーズ， インコーポレイテッド | 肺高血圧症を処置するためのａ２ｂアデノシン受容体アンタゴニストの使用 |
| EP3106163A1 (en) | 2010-10-15 | 2016-12-21 | Gilead Sciences, Inc. | Compositions and methods of treating pulmonary hypertension |
| US20140271680A1 (en) * | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| WO2013130119A1 (en) * | 2012-02-29 | 2013-09-06 | Gilead Sciences, Inc. | Method for treating a pulmonary hypertension condition without companion diagnosis |
| US20130225595A1 (en) * | 2012-02-29 | 2013-08-29 | Gilead Sciences, Inc. | Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis |
| WO2014003678A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil |
| US10518112B2 (en) | 2014-06-18 | 2019-12-31 | Sonivie Ltd. | Method for treating secondary pulmonary hypertension |
| US10576083B2 (en) * | 2015-08-13 | 2020-03-03 | Cipla (UK) Limited | Method of treating pulmonary arterial hypertension |
| RS62011B1 (sr) | 2016-07-15 | 2021-07-30 | Acceleron Pharma Inc | Kompozicije koje sadrže polipeptide actriia za upotrebu u lečenju plućne hipertenzije |
| JP2020532531A (ja) * | 2017-08-30 | 2020-11-12 | ベレロフォン パルス テクノロジーズ エルエルシー | 肺疾患に関連付けられる肺高血圧症の治療のための吸入用一酸化窒素の使用 |
| TW201929841A (zh) * | 2017-12-28 | 2019-08-01 | 美商柏勒洛豐脈衝科技有限責任公司 | 吸入一氧化氮和氧氣用於治療肺高血壓的用途 |
| JP2022532076A (ja) * | 2019-05-06 | 2022-07-13 | アクテリオン ファーマシューティカルズ リミテッド | サルコイドーシス関連肺高血圧症の治療方法 |
| CA3161960A1 (en) | 2019-12-16 | 2021-06-24 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef) |
| RU2729033C1 (ru) * | 2020-02-03 | 2020-08-03 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) | Способ прогнозирования эффективности длительной специфической терапии у пациентов с идиопатической легочной гипертензией и неоперабельной хронической тромбоэмболической легочной гипертензией |
| EP4142731A1 (en) * | 2020-04-28 | 2023-03-08 | Noorik Biopharmaceuticals AG | Treatment of pulmonary complications of coronavirus infections |
| EP3906928A1 (en) * | 2020-05-06 | 2021-11-10 | Noorik Biopharmaceuticals AG | Treatment of pulmonary complications of coronavirus |
| CN114324900A (zh) * | 2021-12-03 | 2022-04-12 | 上海市肺科医院 | 一种促卵泡激素的应用 |
| EP4456897A4 (en) | 2021-12-31 | 2025-12-10 | Tenax Therapeutics Inc | ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION |
| JP2026500956A (ja) * | 2023-01-09 | 2026-01-09 | エスシーファーマシューティカルズ インコーポレイテッド | ループ利尿薬を使用した治療の方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4325525A (en) | 1980-11-13 | 1982-04-20 | General Motors Corporation | Mounting member |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| DE4313412A1 (de) | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| SK287161B6 (sk) | 1997-11-12 | 2010-02-08 | Bayer Healthcare Ag | 2-Fenylsubstituované imidazotriazinóny, spôsob ich výroby, liečivá obsahujúce tieto látky a ich použitie |
| US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| WO2006007213A1 (en) * | 2004-06-23 | 2006-01-19 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
| TW200621261A (en) | 2004-08-26 | 2006-07-01 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| US20060205733A1 (en) * | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| US7511035B2 (en) | 2005-01-25 | 2009-03-31 | Glaxo Group Limited | Antibacterial agents |
| ES2366239T3 (es) * | 2006-04-21 | 2011-10-18 | Pfizer Products Inc. | Piridin[3,4-b]pirazinonas. |
| PL2101777T3 (pl) | 2006-12-12 | 2015-10-30 | Gilead Sciences Inc | Kompozycja do leczenia nadciśnienia płucnego |
| US20080139483A1 (en) * | 2006-12-12 | 2008-06-12 | Gorczynski Richard J | Drug combination for hypertensive disorders |
| JP2010535210A (ja) | 2007-07-31 | 2010-11-18 | ギリード・コロラド・インコーポレーテッド | アンブリセンタンの代謝産物および誘導体 |
| WO2010062640A1 (en) | 2008-10-28 | 2010-06-03 | Gilead Colorado, Inc. | Methods for treating idiopathic pulmonary fibrosis and associated complications |
| EP3106163A1 (en) | 2010-10-15 | 2016-12-21 | Gilead Sciences, Inc. | Compositions and methods of treating pulmonary hypertension |
-
2007
- 2007-12-11 PL PL07855065T patent/PL2101777T3/pl unknown
- 2007-12-11 US US11/953,955 patent/US20080139593A1/en not_active Abandoned
- 2007-12-11 PT PT78550654T patent/PT2101777E/pt unknown
- 2007-12-11 SI SI200731668T patent/SI2101777T1/sl unknown
- 2007-12-11 EP EP15168201.0A patent/EP2952193A1/en not_active Withdrawn
- 2007-12-11 JP JP2009541511A patent/JP2010512414A/ja not_active Withdrawn
- 2007-12-11 EP EP07855065.4A patent/EP2101777B1/en not_active Revoked
- 2007-12-11 HU HUE07855065A patent/HUE025355T2/en unknown
- 2007-12-11 ES ES07855065.4T patent/ES2544724T3/es active Active
- 2007-12-11 WO PCT/US2007/087058 patent/WO2008073928A1/en not_active Ceased
- 2007-12-11 CA CA2669536A patent/CA2669536C/en active Active
- 2007-12-11 DK DK07855065.4T patent/DK2101777T3/en active
- 2007-12-11 AU AU2007333115A patent/AU2007333115B2/en active Active
-
2010
- 2010-02-17 US US12/706,818 patent/US20100152217A1/en not_active Abandoned
-
2011
- 2011-06-16 US US13/162,137 patent/US8377933B2/en active Active
-
2012
- 2012-12-21 US US13/723,758 patent/US20130116257A1/en not_active Abandoned
-
2014
- 2014-02-17 US US14/182,208 patent/US9474752B2/en active Active
-
2015
- 2015-04-24 US US14/695,775 patent/US9504685B2/en active Active
-
2016
- 2016-05-20 LU LU93081C patent/LU93081I2/fr unknown
- 2016-05-20 CY CY2016017C patent/CY2016017I2/el unknown
- 2016-05-20 HU HUS1600027C patent/HUS1600027I1/hu unknown
- 2016-06-06 HK HK16106422.7A patent/HK1218393A1/en unknown
- 2016-11-23 US US15/360,304 patent/US9993475B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010512414A5 (enExample) | ||
| Korn et al. | Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist | |
| AU2013299625B2 (en) | Treatment of immune-related and inflammatory diseases | |
| Wang et al. | The role of aldosterone in OSA and OSA-related hypertension | |
| Karlberg et al. | Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension | |
| Croom et al. | Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy | |
| Eguchi et al. | Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension | |
| WO2006059108A3 (en) | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES | |
| WO2004017896A3 (en) | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist | |
| JP2011515349A5 (enExample) | ||
| RU2012110592A (ru) | Соединения и способ снижения мочевой кислоты | |
| Melian et al. | Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension | |
| JP2003519228A5 (enExample) | ||
| US20060293309A1 (en) | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors | |
| JP2009518415A5 (enExample) | ||
| JP2013528649A5 (enExample) | ||
| JP2018502126A5 (enExample) | ||
| Destro et al. | Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring | |
| Spinar et al. | Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the MEDINA study) | |
| Lacourcière et al. | Antihypertensive effects of amlodipine and hydrochlorothiazide in elderly patients with ambulatory hypertension | |
| Fogari et al. | Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study | |
| AU2006311574A1 (en) | Use of cicletanine and other furopyridines for treatment of hypertension | |
| Wenzel et al. | Treatment of Arterial Hypertension | |
| AU2015305430A1 (en) | Method for treating hyperhidrosis | |
| JPWO2004098611A1 (ja) | 増強剤 |